StockData
Zevra Therapeutics, Inc. logo

Zevra Therapeutics, Inc. (ZVRA) stock

ZVRANasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 15/3060% below fair value
$8.76−0.31 (-3.42%)

Close on Nov 20, 2026Market cap $520.20MP/E 9.4Yield –

Zevra Therapeutics pe ratio

The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.

Zevra Therapeutics's pe ratio was 12.7× on Nov 11, 2026, against 17.9× a year earlier.

PE Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 202612.7×−6.3
2025Dec 31, 202519.1×–

More Zevra Therapeutics figures

See a number that looks wrong?